
Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP
Use this educational tool to explore the daily burden of loss of smell for patients with CRSwNP.

Dr. Amy Paller discusses the clinical utility of TARC measurements in AD management at EADV 2025

Join Dr. Leonard Bacharier as he discusses the definition of clinical remission in pediatric asthma and how it can represent a potential target in pediatric asthma management.

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.

ADVENT Symposia brought global experts together to explore the latest advances in pediatric atopic dermatitis (AD), the shared and unique drivers of AD, prurigo nodularis (PN), and chronic spontaneous urticaria (CSU), and the pathology and patient management of PN.

Join experts G. Walter Canonica, Vibeke Backer, and Joaquim Mullol for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.
In this ADVENT symposium at the 2024 EADV meeting, Dr. Donna Culton focuses on the challenges of diagnosis and the unmet needs for patients with BP.

In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Perla Lansang reviews the key considerations for management of AD that is uncontrolled with topical therapies in children and the criteria to determine whether a patient is indicated for systemic therapy

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson explains how both clinical and subclinical disease control are critical for achieving true disease modification in atopic dermatitis, emphasizing the role of biomarkers in predicting long-term outcomes and guiding treatment decisions.

Engage with experts Klaus Rabe, Stephanie Christenson, and Paola Rogliani in an educational symposium to explore the inflammatory pathways and phenotypes of COPD, investigate the genetic associations of IL-33 and COPD, examine early preclinical findings, and review ongoing research on the role of IL-33 in COPD.

In this educational presentation, Profs. Vibeke Backer and Sietze Reitsma cover key aspects of type 2 inflammation and its role in the pathogenesis and management of CRSwNP and practical strategies for optimizing disease control and improving patient outcomes.